Table 1 Outcomes which were assessed
Trials | Outcomes reported | Follow-up periods | Drugs which were used | Dosage of rivaroxaban |
|---|---|---|---|---|
ATLAS-ACS 2 TIMI 51 [11] | Cardiac death + stroke + MI (composite endpoint), cardiac death, MI, stroke, all-cause death, ST, TIMI minor and major bleeding, Intracranial hemorrhage, fatal bleeding | 13 to 31 months | Rivaroxaban + DAPT versus DAPT (aspirin + clopidogrel) | 2.5 mg or 5 mg twice daily |
GEMINI-ACS-1 [12] | Cardiac death + stroke + MI + ST (composite endpoint), cardiac death, MI, stroke, all-cause death, ST (definite + probable), TIMI minor and major bleeding, fatal bleeding, intracranial hemorrhage, ISTH major bleeding | 1 year | Ribaroxaban + clopidogrel/ticagrelor versus aspirin + clopidogrel/ticagrelor | 2.5 mg twice daily |
COMPASS [13] | Cardiac death + stroke + MI (composite endpoint), all-cause death, cardiac death, stroke, MI, fatal bleeding, intracranial hemorrhage, major bleeding according to ISTH criteria | 23 months | Rivaroxaban + aspirin versus aspirin alone | 2.5 mg or 5 mg twice daily |
ATLAS-ACS-TIMI 46 [14] | TIMI minor and major bleeding, death + MI + stroke (composite endpoint) | 6 months | Rivaroxaban + DAPT or aspirin versus DAPT (aspirin + clopidogrel) | 5 to 20 mg once daily or the same total dose given twice daily |